Iterum Therapeutics PLC ITRM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ITRM is a good fit for your portfolio.
News
-
Thinking about buying stock in Akebia Therapeutics, Mind Medicine, ATAI Life Sciences, Doma Holdings, or Iterum Therapeutics?
-
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
-
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
-
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
-
Iterum Therapeutics Provides Business Update
-
Iterum Therapeutics Says UTI Drug Trial Met Primary Endpoint
-
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
Trading Information
- Previous Close Price
- $1.43
- Day Range
- $1.46–1.60
- 52-Week Range
- $0.62–2.50
- Bid/Ask
- $1.50 / $1.64
- Market Cap
- $25.95 Mil
- Volume/Avg
- 197,643 / 217,092
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 14
- Website
- https://www.iterumtx.com
Valuation
|
Metric
|
ITRM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ITRM
|
|---|---|
Quick Ratio | 1.79 |
Current Ratio | 1.89 |
Interest Coverage | −25.44 |
Quick Ratio
ITRM
Profitability
|
Metric
|
ITRM
|
|---|---|
Return on Assets (Normalized) | −97.86% |
Return on Equity (Normalized) | −463.27% |
Return on Invested Capital (Normalized) | −127.95% |
Return on Assets
ITRM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qmdrfkzm | Hbbj | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qvdwmcnv | Grsvxx | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wgykbly | Mfpfpfp | $98.8 Bil | |
MRNA
| Moderna Inc | Mklqvxnr | Wfn | $38.8 Bil | |
ARGX
| argenx SE ADR | Xwqnybyww | Jnk | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Nzgxnmdg | Hqs | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cjstzmrs | Lrrtdf | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kqwlqpnx | Gfbqg | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rkcwfhwkb | Lmgbtw | $12.4 Bil | |
INCY
| Incyte Corp | Svjfqnrg | Zdzxmh | $11.9 Bil |